DS-8273a + nivolumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colorectal Neoplasm
Conditions
Colorectal Neoplasm
Trial Timeline
Dec 1, 2016 → Sep 22, 2017
NCT ID
NCT02991196About DS-8273a + nivolumab
DS-8273a + nivolumab is a phase 1 stage product being developed by Daiichi Sankyo for Colorectal Neoplasm. The current trial status is terminated. This product is registered under clinical trial identifier NCT02991196. Target conditions include Colorectal Neoplasm.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02991196 | Phase 1 | Terminated |
| NCT02983006 | Phase 1 | Completed |
Competing Products
20 competing products in Colorectal Neoplasm